Venus Remedies secures Mexico patent for Potentox
The patent grants exclusive rights till 2025 for the drug to the company.
Chandigarh, June 18, 2013: Venus Remedies had received the patent from Mexico for its novel antibiotic Potentox. It may be noted here that the patent has been granted by the Mexican Institute of Industrial Property (IMPI) and the patent protects the composition of Potentox.
The company said that the patent provides an exclusive period till 2025 to the drug. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, as per the company.
It is worth mentioning here that Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes.